scholarly journals Bariatric Surgery Induces Weight Loss but Does Not Improve Glycemic Control in Patients With Type 1 Diabetes

Diabetes Care ◽  
2014 ◽  
Vol 37 (8) ◽  
pp. e173-e174 ◽  
Author(s):  
Matthias Lannoo ◽  
Bruno Dillemans ◽  
Yves Van Nieuwenhove ◽  
Steffen Fieuws ◽  
Chantal Mathieu ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Type 1 Diabetes ◽  
Glycemic Control

scholarly journals A Systematic Review and Meta-Analysis of Outcomes for Type 1 Diabetes after Bariatric Surgery

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Alexandra Chow ◽  
Noah J. Switzer ◽  
Jerry Dang ◽  
Xinzhe Shi ◽  
Christopher de Gara ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Meta Analysis ◽  
Insulin Requirement ◽  
Study Endpoint ◽  
Inclusion Criteria ◽  
Comprehensive Search ◽  
Bariatric Surgical Procedure

Background. The utility of bariatric surgery in type 1 diabetes remains controversial. The aim of the present study is to evaluate glycemic control outcomes in obese patients with type 1 diabetes after bariatric surgery.Methods. A comprehensive search of electronic databases was completed. Inclusion criteria included human adult subjects with BMI ≥35 kg/m2and a confirmed diagnosis of type 1 diabetes who underwent a bariatric surgical procedure.Results. Thirteen primary studies (86 patients) were included. Subjects had a mean age of41.16±6.76years with a mean BMI of42.50±2.65 kg/m2. There was a marked reduction in BMI postoperatively at 12 months and at study endpoint to29.55±1.76 kg/m2(P<0.00001) and30.63±2.09 kg/m2(P<0.00001), respectively. Preoperative weighted mean total daily insulin requirement was98±26 IU/d, which decreased significantly to36±15 IU/d (P<0.00001) and42±11 IU/d (P<0.00001) at 12 months and at study endpoint, respectively. An improvement inHbA1cwas also seen from8.46±0.78% preoperatively to7.95±0.55% (P=0.01) and8.13±0.86% (P=0.03) at 12 months and at study endpoint, respectively.Conclusion. Bariatric surgery in patients with type 1 diabetes leads to significant reductions in BMI and improvements in glycemic control.

Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus

2019 ◽  
Vol 76 (21) ◽  
pp. 1739-1748
Author(s):  
Justinne Guyton ◽  
Michelle Jeon ◽  
Amie Brooks
Keyword(s):  
Diabetes Mellitus ◽  
Weight Loss ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Type 1 Diabetes Mellitus ◽  
Alpha Cell ◽  
Cell Dysfunction ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Abstract Purpose The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed. Summary Currently approved treatment options for glycemic control in T1DM include insulin, which combats insulin deficiency but does not effectively target disease progression or alpha cell dysfunction; and pramlintide, whose use requires multiple daily doses and involves a high likelihood of gastrointestinal side effects. GLP-1 RAs have a unique mechanism of action in T1DM, addressing alpha cell dysfunction and thereby suppressing inappropriate glucagon secretion. GLP-1 RA dosing varies from once weekly to twice daily, and the class is well tolerated in patients with type 2 diabetes. Among the GLP-1 RAs, exenatide and liraglutide have been studied in patients with T1DM, with published evidence consistently demonstrating weight loss, decreases in total daily insulin requirements, and modest improvements in glycemic control. GLP-1 RA therapy appears to be well tolerated in patients with T1DM and is associated with nonsignificant increases in hypoglycemia risk. Conclusion GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM. Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy. Further studies are warranted to evaluate these agents’ potential impact on clinical outcomes such as microvascular and macrovascular complications.

Bariatric Surgery in Obese Patients with Type 1 Diabetes: Effects on Weight Loss and Metabolic Control

2016 ◽  
Vol 26 (10) ◽  
pp. 2370-2378 ◽  
Author(s):  
Pauline Faucher ◽  
Christine Poitou ◽  
Claire Carette ◽  
Sophie Tezenas du Montcel ◽  
Charles Barsamian ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Type 1 Diabetes ◽  
Metabolic Control ◽  
Obese Patients

The Role of Secrecy and Disclosure in Type 1 Diabetes Adherence and Glycemic Control

2013 ◽  
Author(s):  
P. Osborn ◽  
C. A. Berg ◽  
A. E. Hughes ◽  
P. Pham ◽  
D. J. Wiebe
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control

Glycemic control influences on academic performance in youth with Type 1 diabetes.

2019 ◽  
Vol 34 (6) ◽  
pp. 646-655
Author(s):  
Madison F. Knight ◽  
Michelle M. Perfect
Keyword(s):  
Type 1 Diabetes ◽  
Academic Performance ◽  
Glycemic Control

Association of dislipidemia and glycemic control in patients with type 1 diabetes mellitus

2018 ◽  
Author(s):  
Elena Makhlina ◽  
Tatiana Mokhort ◽  
Yana Navmenova ◽  
Marina Kaplieva ◽  
Irina Savosteeva
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Type 1 Diabetes Mellitus

1065-P: The Effect of a Closed-Loop Insulin Delivery System on Glycemic Control in Type 1 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1065-P ◽  
Author(s):  
ANASTASIOS KOUTSOVASILIS ◽  
ALEXIOS SOTIROPOULOS ◽  
ANASTASIA ANTONIOU ◽  
VASILIOS KORDINAS ◽  
DESPINA PAPADAKI ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Delivery System ◽  
Closed Loop ◽  
Insulin Delivery ◽  
Insulin Delivery System
Sign in / Sign up

Export Citation Format

Share Document